

# ForPatients

by Roche

Pancreatic Ductal Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC) Gastric Cancer  
Metastatic Solid Tumors

## A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

**Trial Status**  
Recruiting

**Trial Runs In**  
8 Countries

**Trial Identifier**  
NCT05867121 2022-502615-11-00  
GO44010

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

The purpose of this study is to evaluate the safety and tolerability of RO7496353 when administered in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The study will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT05867121 2022-502615-11-00 GO44010**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---